|1.||Naber, D: 6 articles (08/2012 - 02/2005)|
|2.||Lambert, M: 5 articles (08/2012 - 02/2005)|
|3.||Naber, Dieter: 5 articles (01/2011 - 09/2006)|
|4.||Karow, A: 3 articles (08/2012 - 11/2009)|
|5.||Moritz, S: 3 articles (08/2012 - 02/2005)|
|6.||Ballesteros, Javier: 3 articles (02/2012 - 01/2011)|
|7.||Mauriño, Jorge: 3 articles (02/2012 - 01/2011)|
|8.||Carpiniello, Bernardo: 2 articles (01/2014 - 01/2012)|
|9.||Pinna, Federica: 2 articles (01/2014 - 01/2012)|
|10.||Huber, Christian G: 2 articles (10/2013 - 05/2009)|
|1.||Schizophrenia (Dementia Praecox)
08/01/2012 - "Symptoms (PANSS), functional outcome (FROGS, GAF), subjective well-being (SWN-K) and other characteristics were assessed in 131 patients with schizophrenia (DSM-IV) within the European Group on Functional Outcomes and Remission in Schizophrenia (EGOFORS) project. "
11/01/2009 - "Response and remission rates were assessed in 528 severely ill patients with schizophrenia at baseline, week 2, 4 and 12 using PANSS, SWN-K, CGI-S, and SOFAS. "
01/01/2007 - "In a multicenter observational study of 2960 patients with DSM-IV-defined schizophrenia recruited between January and December 2001, subjective well-being was measured during 12 months with the Subjective Well-Being Under Neuroleptic Treatment Scale, short version (SWN-K). "
10/01/2015 - "Reductions of monthly mean values of Scale for the Assessment of Positive Symptoms (SAPS) [repeated measures analysis of variance (rm-ANOVA): p < 0.0001] and Scale for Assessment of Negative Symptoms (SANS) (p < 0.0001), increase of monthly mean values of Subjective Well-Being Under Neuroleptic Treatment Scale (SWN) (p < 0.0001) and Schizophrenia Quality of Life Scale (S-QoL) (p < 0.01) were observed. "
03/30/2013 - "The SWN scale and other relevant assessments were completed by 545 schizophrenia patients, 541 siblings, 75 parents, and 280 healthy controls. "
|2.||Psychomotor Agitation (Akathisia)
09/01/2009 - "In correlation analysis controlling for relevant variables, the SWN score had significant negative correlations with the following subscale scores of the LUNSERS: extrapyramidal side effect (EPS) (r = -0.54, P < 0.01), akathisia (r = -0.46, P < 0.05), and autonomic adverse effect (r = -0.44, P < 0.05). "
12/01/2008 - "Baseline and outcome assessment included Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression Severity of Illness Subscale (CGI-S) and Global Improvement Subscale (CGI-I), Subjective Well-being on Neuroleptics Scale (SWN), Simpson-Angus Extrapyramidal Rating Scale (SAS), Barnes Akathisia Rating Scale (BARS) and UKU Side Effects Rating Scale (UKU). "
|3.||Bipolar Disorder (Mania)
03/01/2011 - "End point severity of depression was associated with the end point SWN total score explaining additional 26% of SWN total score variance, whereas severity of mania was inversely associated with SWN total score. "
03/01/2011 - "At baseline, depression explained 24% and mania explained an additional 16% of baseline SWN variance. "
03/01/2011 - "The Young's Mania Rating Scale (YMRS) and the Hamilton Rating Scale for Depression (HAM-D) were used to determine affective symptoms, while subjective well-being was assessed by subjective well-being under neuroleptic (SWN). "
05/01/2009 - "2175 patients with schizophrenia-spectrum (SZ, n=1681), schizoaffective (SA, n=249), and bipolar disorder (BPD, n=245) were treated with quetiapine over 6 months and assessed with the Clinical Global Impression-Severity of illness Scale (CGI-S) and the Subjective Wellbeing under Neuroleptic Treatment Scale (SWN-K). "
|4.||Psychotic Disorders (Schizoaffective Disorder)
04/01/2009 - "The SMRA showed that SWN scores were negatively correlated with the severity of the psychoses (BPRS scores), while the DAI-30 scores were negatively correlated with the severity of the psychoses and positively correlated both with the length of drug treatment and with the use of olanzapine. "
|1.||Antipsychotic Agents (Antipsychotics)
|3.||Silver Sulfadiazine (SSD)